Clinical Use of Quantitative Computed Tomography (QCT) of the Hip in the Management of Osteoporosis in Adults: The 2015 ISCD Official Positions-Part I

Journal of Clinical Densitometry

Volumn 18, Issue 3, 2015, Pages 338-358

  Engelke, Klaus ^a,b   Lang, Thomas ^c   Khosla, Sundeep ^d   Qin, Ling ^e   Zysset, Philippe ^f   Leslie, William D ^g   Shepherd, John A ^c   Schousboe, John T ^h,i  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b BioClinica Inc   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Mayo Clinic   (United States)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^f UNIVERSITY OF BERN   (Switzerland)

^g UNIVERSITY OF MANITOBA   (Canada)

^h PARK NICOLLET CLINIC   (United States)

ⁱ UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Bone mineral density (BMD); Osteoporosis; Position; Proximal femur; Quantitative computed tomography (QCT)

Indexed keywords

ACETABULUM; ARTICLE; BONE DENSITY; COMPUTER ASSISTED TOMOGRAPHY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMUR; FEMUR NECK; FINITE ELEMENT ANALYSIS; FRAGILITY FRACTURE; HIP; HUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; QUANTITATIVE COMPUTED TOMOGRAPHY; RISK ASSESSMENT; SPINE; ADULT; COMPLICATION; CONSENSUS; FRACTURES, BONE; MEDICAL SOCIETY; PHOTON ABSORPTIOMETRY; PRACTICE GUIDELINE; RADIOGRAPHY;

ABSORPTIOMETRY, PHOTON; ACETABULUM; ADULT; BONE DENSITY; CONSENSUS; FEMUR; FRACTURES, BONE; HUMANS; OSTEOPOROSIS; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; SOCIETIES, MEDICAL; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84946901275     PISSN: 10946950     EISSN: 15590747     Source Type: Journal    
DOI: 10.1016/j.jocd.2015.06.012     Document Type: Article

References (72)

1. Engelke K., Adams J.E., Armbrecht G., et al. Clinical use of quantitative computed tomography and peripheral quantitative computed tomography in the management of osteoporosis in adults: the 2007 ISCD Official Positions. J Clin Densitom 2008, 11(1):123-162.
2. Adams J.E., Engelke K., Zemel B.S., et al. Quantitative computer tomography in children and adolescents: the 2013 ISCD Pediatric Official Positions. J Clin Densitom 2014, 17(2):258-274.
3. Engelke K. Assessment of bone quality and strength with new technologies. Curr Opin Endocrinol Diabetes Obes 2012, 19(6):474-482.
4. Treece G.M., Poole K.E., Gee A.H. Imaging the femoral cortex: thickness, density and mass from clinical CT. Med Image Anal 2012, 16(5):952-965.
5. Brett A. Private communication 2014, Mindways Inc, Austin, TX, USA.
6. Cann C.E., Adams J.E., Brown J.K., Brett A.D. CTXA hip-an extension of classical DXA measurements using quantitative CT. PLoS One 2014, 9(3). p. e91904.
7. Lewiecki E.M., Keaveny T.M., Kopperdahl D.L., et al. Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 2009, 94(1):171-180.
8. Engelke K., Nagase S., Fuerst T., et al. The effect of the cathepsin K inhibitor ONO-5334 on trabecular and cortical bone in postmenopausal osteoporosis: the OCEAN study. J Bone Miner Res 2014, 29(3):629-638.
9. Fitzpatrick L.A., Dabrowski C.E., Cicconetti G., et al. Ronacaleret, a calcium-sensing receptor antagonist, increases trabecular but not cortical bone in postmenopausal women. J Bone Miner Res 2012, 27(2):255-262.
10. Engelke K., Fuerst T., Dardzinski B., et al. Odanacatib treatment affects trabecular and cortical bone in the femur of postmenopausal women - results of a 2-year placebo-controlled trial. J Bone Miner Res 2014, 30(1):30-38.
11. Genant H.K., Libanati C., Engelke K., et al. Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab. Bone 2013, 56(2):482-488.
12. Engelke K., Fuerst T., Dasic G., et al. Regional distribution of spine and hip QCT BMD responses after one year of once-monthly ibandronate in postmenopausal osteoporosis. Bone 2010, 46(6):1626-1632.
13. Eastell R., Lang T., Boonen S., et al. Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial. Osteoporos Int 2010, 21(7):1277-1285.
14. Miller P.D., Delmas P.D., Lindsay R., et al. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab 2008, 93(10):3785-3793.
15. Yang L., Sycheva A.V., Black D.M., Eastell R. Site-specific differential effects of once-yearly zoledronic acid on the hip assessed with quantitative computed tomography: results from the HORIZON Pivotal Fracture Trial. Osteoporos Int 2013, 24(1):329-338.
16. Poole K.E., Treece G.M., Gee A.H., et al. Denosumab rapidly increases cortical bone in key locations of the semur: A 3D bone mapping study in women with osteoporosis. J Bone Miner Res 2015, 30(1):46-54.
17. Borggrefe J., GraeffC., Nickelsen T.N., et al. Quantitative computed tomographic assessment of the effects of 24 months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: results from the EUROFORS study. J Bone Miner Res 2010, 25(3):472-481.
18. GraeffC., Timm W., Nickelsen T.N., et al. Monitoring teriparatide-associated changes in vertebral microstructure by high-resolution CT in vivo: results from the EUROFORS study. J Bone Miner Res 2007, 22(9):1426-1433.
19. Keaveny T.M., Donley D.W., Hoffmann P.F., et al. Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res 2007, 22(1):149-157.
20. Brixen K., Chapurlat R., Cheung A.M., et al. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial. J Clin Endocrinol Metab 2013, 98(2):571-580.
21. McClung M.R., Zanchetta J.R., Hoiseth A., et al. Denosumab densitometric changes assessed by quantitative computed tomography at the spine and hip in postmenopausal women with osteoporosis. J Clin Densitom 2013, 16(2):250-256.
22. Cosman F., Keaveny T.M., Kopperdahl D., et al. Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene. J Bone Miner Res 2013, 28(6):1328-1336.
23. Muschitz C., Kocijan R., Fahrleitner-Pammer A., et al. Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density-the CONFORS Study. J Bone Miner Res 2014, 29(8):1777-1785.
24. Zhu K., Meng X., Kerr D.A., et al. The effects of a two-year randomized, controlled trial of whey protein supplementation on bone structure, IGF-1, and urinary calcium excretion in older postmenopausal women. J Bone Miner Res 2011, 26(9):2298-2306.
25. Johannesdottir F., Poole K.E., Reeve J., et al. Distribution of cortical bone in the femoral neck and hip fracture: a prospective case-control analysis of 143 incident hip fractures; the AGES-REYKJAVIK Study. Bone 2011, 48(6):1268-1276.
26. Yang L., Burton A.C., Bradburn M., et al. Distribution of bone density in the proximal femur and its association with hip fracture risk in older men: the osteoporotic fractures in men (MrOS) study. J Bone Miner Res 2012, 27(11):2314-2324.
27. Rianon N.J., Lang T.F., Siggeirsdottir K., et al. Fracture risk assessment in older adults using a combination of selected quantitative computed tomography bone measures: a subanalysis of the Age, Gene/Environment Susceptibility-Reykjavik Study. J Clin Densitom 2014, 17(1):25-31.
28. Black D.M., Bouxsein M.L., Marshall L.M., et al. Proximal femoral structure and the prediction of hip fracture in men: a large prospective study using QCT. J Bone Miner Res 2008, 23(8):1326-1333.
29. Bousson V.D., Adams J., Engelke K., et al. In vivo discrimination of hip fracture with quantitative computed tomography: results from the prospective European Femur Fracture Study (EFFECT). J Bone Miner Res 2011, 26(4):881-893.
30. Cheng X., Li J., Lu Y., et al. Proximal femoral density and geometry measurements by quantitative computed tomography: association with hip fracture. Bone 2007, 40(1):169-174.
31. Ito M., Wakao N., Hida T., et al. Analysis of hip geometry by clinical CT for the assessment of hip fracture risk in elderly Japanese women. Bone 2010, 46(2):453-457.
32. Nishiyama K.K., Ito M., Harada A., Boyd S.K. Classification of women with and without hip fracture based on quantitative computed tomography and finite element analysis. Osteoporos Int 2014, 25(2):619-626.
33. Cody D.D., Hou F.J., Divine G.W., Fyhrie D.P. Femoral structure and stiffness in patients with femoral neck fracture. J Orthop Res 2000, 18(3):443-448.
34. Guglielmi G., Floriani I., Torri V., et al. Effect of spinal degenerative changes on volumetric bone mineral density of the central skeleton as measured by quantitative computed tomography. Acta Radiol 2005, 46(3):269-275.
35. Lang T.F., Guglielmi G., van Kuijk C., et al. Measurement of bone mineral density at the spine and proximal femur by volumetric quantitative computed tomography and dual-energy X-ray absorptiometry in elderly women with and without vertebral fractures. Bone 2002, 30(1):247-250.
36. Kim K.M., Brown J.K., Kim K.J., et al. Differences in femoral neck geometry associated with age and ethnicity. Osteoporos Int 2011, 22(7):2165-2174.
37. Poole K.E., Mayhew P.M., Rose C.M., Brown J.K., et al. Changing structure of the femoral neck across the adult female lifespan. J Bone Miner Res 2010, 25(3):482-491.
38. Nicks K.M., Amin S., Melton L.J. Three-dimensional structural analysis of the proximal femur in an age-stratified sample of women. Bone 2013, 55(1):179-188.
39. Johannesdottir F., Aspelund T., Reeve J., et al. Similarities and differences between sexes in regional loss of cortical and trabecular bone in the mid-femoral neck: the AGES-Reykjavik longitudinal study. J Bone Miner Res 2013, 28(10):2165-2176.
40. Lang T.F., Sigurdsson S., Karlsdottir G., et al. Age-related loss of proximal femoral strength in elderly men and women: the Age Gene/Environment Susceptibility Study-Reykjavik. Bone 2012, 50(3):743-748.
41. Srinivasan B., Kopperdahl D.L., Amin S., et al. Relationship of femoral neck areal bone mineral density to volumetric bone mineral density, bone size, and femoral strength in men and women. Osteoporos Int 2012, 23(1):155-162.
42. Muschitz C., Kocijan R., Fahrleitner-Pammer A., et al. Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density. J Bone Miner Res 2013, 28(1):196-205.
43. van Vonderen M.G., Lips P., van Agtmael M.A., et al. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. AIDS 2009, 23(11):1367-1376.
44. Keaveny T.M., Hoffmann P.F., Singh M., et al. Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans. J Bone Miner Res 2008, 23(12):1974-1982.
45. Lian K.C., Lang T.F., Keyak J.H., et al. Differences in hip quantitative computed tomography (QCT) measurements of bone mineral density and bone strength between glucocorticoid-treated and glucocorticoid-naive postmenopausal women. Osteoporos Int 2005, 16(6):642-650.
46. Yang L., Udall W.J., McCloskey E.V., Eastell R. Distribution of bone density and cortical thickness in the proximal femur and their association with hip fracture in postmenopausal women: a quantitative computed tomography study. Osteoporos Int 2014, 25(1):251-263.
47. Amin S., Kopperdhal D.L., Melton L.J., et al. Association of hip strength estimates by finite-element analysis with fractures in women and men. J Bone Miner Res 2011, 26(7):1593-1600.
48. Black D.M., Greenspan S.L., Ensrud K.E., et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003, 349(13):1207-1215.
49. Bauer D.C., Garnero P., Bilezikian J.P., et al. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2006, 91(4):1370-1375.
50. Black D.M., Bilezikian J.P., Ensrud K.E., et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 2005, 353(6):555-565.
51. Greenspan S.L., Bone H.G., Ettinger M.P., et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 2007, 146(5):326-339.
52. Christiansen B.A., Kopperdahl D.L., Kiel D.P., et al. Mechanical contributions of the cortical and trabecular compartments contribute to differences in age-related changes in vertebral body strength in men and women assessed by QCT-based finite element analysis. J Bone Miner Res 2011, 26(5):974-983.
53. GraeffC., Chevalier Y., Charlebois M., et al. Improvements in vertebral body strength under teriparatide treatment assessed in vivo by finite element analysis: results from the EUROFORS study. J Bone Miner Res 2009, 24(10):1672-1680.
54. Weber N.K., Fidler J.L., Keaveny T.M., et al. Validation of a CT-derived method for osteoporosis screening in IBD patients undergoing contrast-enhanced CT enterography. Am J Gastroenterol 2014, 109(3):401-408.
55. U.o. S., UK FRAX ® WHO Fracture Risk Assessment Tool 2015, World Health Organization Collaborating Centre for Metabolic Bone Diseases, Available at:, Accessed: July 16, 2015. http://www.shef.ac.uk/FRAX/.
56. The 2007 Recommendations of the International Commission on Radiological Protection ICRP Publication 103 Ann. ICRP 37 (2-4), 2007.
57. Lang T.F., Keyak J.H., Heitz M.W., et al. Volumetric quantitative computed tomography of the proximal femur: precision and relation to bone strength. Bone 1997, 21(1):101-108.
58. Li W., Sode M., Saeed I., Lang T. Automated registration of hip and spine for longitudinal QCT studies: integration with 3D densitometric and structural analysis. Bone 2006, 38(2):273-279.
59. Gerner B., Töpfer D., Museyko O., Engelke K. Impact of Segmentation in Quantitative Computed Tomography in Bildverarbeitung für die Medizin 2013 2013, Springer, Heidelberg, Germany.
60. Cummings S.R., Bates D., Black D.M. Clinical use of bone densitometry: scientific review. JAMA 2002, 288(15):1889-1897.
61. Gluer C.C., Lu Y., Engelke K. Quality and performance measures in bone densitometry: part 2: fracture risk. Osteoporos Int 2006, 17(10):1449-1458.
62. Osteologie, Osteoporose-Leitlinie 2006, DVO and -.D.d.d.w. G.f, Schattauer, Stuttgart.
63. Bousson V., Le Bras A., Roqueplan F., et al. Volumetric quantitative computed tomography of the proximal femur: relationships linking geometric and densitometric variables to bone strength. Role for compact bone. Osteoporos Int 2006, 17(6):855-864.
64. Khoo B.C., Brown K., Cann C., et al. Comparison of QCT-derived and DXA-derived areal bone mineral density and T scores. Osteoporos Int 2009, 20(9):1539-1545.
65. Cheng X., Wang L., Wang Q., et al. Validation of quantitative computed tomography-derived areal bone mineral density with dual energy X-ray absorptiometry in an elderly Chinese population. Chin Med J (Engl) 2014, 127(8):1445-1449.
66. Looker A.C., Orwoll E.S., Johnston C.C., et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 1997, 12(11):1761-1768.
67. Pickhardt P., Bodeen G., Brett A., et al. Comparison of femoral neck BMD evaluation obtained using lunar DXA and QCT with asynchronous calibration from CT colonography. J Clin Densitom 2015, 18(1):5-12.
68. Keaveny T.M., Kopperdahl D.L., Melton L.J., et al. Age-dependence of femoral strength in white women and men. J Bone Miner Res 2010, 25(5):994-1001.
69. Kopperdahl D.L., Aspelund T., Hoffmann P.F., et al. Assessment of incident spine and hip fractures in women and men using finite element analysis of CT scans. J Bone Miner Res 2014, 29(3):570-580.
70. Keyak J.H., Sigurdsson S., Karlsdottir G., et al. Male-female differences in the association between incident hip fracture and proximal femoral strength: a finite element analysis study. Bone 2011, 48(6):1239-1245.
71. Black D.M., Cummings S.R., Karpf D.B., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996, 348(9041):1535-1541.
72. Shepherd J.A., Lu Y. A generalized least significant change for individuals measured on different DXA systems. J Clin Densitom 2007, 10(3):249-258.